艰难梭菌感染患者对毒素A和毒素B的IgG抗体反应。
IgG antibody response to toxins A and B in patients with Clostridium difficile infection.
作者信息
Wullt M, Norén T, Ljungh A, Åkerlund T
机构信息
Infectious Diseases Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
出版信息
Clin Vaccine Immunol. 2012 Sep;19(9):1552-4. doi: 10.1128/CVI.00210-12. Epub 2012 Jul 11.
Abstract
IgG antibodies against Clostridium difficile toxins A and B were followed in controls and in patients with an initial C. difficile infection (CDI). Of the 50 CDI patients, 38 were cured and 12 developed recurrence. Compared to controls, patients had significantly lower anti-toxin A and B IgGs at inclusion, but the subsequent levels rose slightly regardless of clinical outcome. The results imply that the general serum reactivity against toxins A and B in the population reduces the risk of CDI, which suggests implications for vaccine strategies.
摘要
在对照组以及初次感染艰难梭菌（CDI）的患者中，对针对艰难梭菌毒素A和B的IgG抗体进行了跟踪研究。在50例CDI患者中，38例治愈，12例复发。与对照组相比，患者在纳入研究时抗毒素A和B的IgG水平显著较低，但无论临床结果如何，随后这些水平均略有上升。结果表明，人群中针对毒素A和B的总体血清反应性可降低CDI风险，这对疫苗策略具有启示意义。
相似文献
1
IgG antibody response to toxins A and B in patients with Clostridium difficile infection.艰难梭菌感染患者对毒素A和毒素B的IgG抗体反应。
Clin Vaccine Immunol. 2012 Sep;19(9):1552-4. doi: 10.1128/CVI.00210-12. Epub 2012 Jul 11.
2
Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.艰难梭菌相关腹泻、炎症性肠病和囊性纤维化患者对艰难梭菌毒素 A 和 B 的循环抗体和记忆 B 细胞反应。
PLoS One. 2013 Sep 10;8(9):e74452. doi: 10.1371/journal.pone.0074452. eCollection 2013.
3
Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.新型艰难梭菌抗毒素（TcdA和TcdB）人源化单克隆抗体在体外对多种临床菌株具有中和作用，并在仓鼠孢子攻击模型中展现出体内效力。
PLoS One. 2016 Jun 23;11(6):e0157970. doi: 10.1371/journal.pone.0157970. eCollection 2016.
4
The impact of existing total anti-toxin B IgG immunity in outcomes of recurrent Clostridioides difficile infection.已有全抗毒素 B IgG 免疫对复发性艰难梭菌感染结局的影响。
Anaerobe. 2024 Jun;87:102842. doi: 10.1016/j.anaerobe.2024.102842. Epub 2024 Mar 28.
5
Anti-toxin antibody is not associated with recurrent Clostridium difficile infection.抗毒素抗体与复发性艰难梭菌感染无关。
Anaerobe. 2021 Feb;67:102299. doi: 10.1016/j.anaerobe.2020.102299. Epub 2020 Nov 21.
6
Development of a new serological assay for the diagnosis of Clostridium difficile infections with prognostic value.开发一种新的血清学检测方法，用于诊断具有预后价值的艰难梭菌感染。
J Microbiol Methods. 2019 Dec;167:105777. doi: 10.1016/j.mimet.2019.105777. Epub 2019 Nov 13.
7
Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection.灵敏的检测方法能够检测出健康受试者以及艰难梭菌感染患者血清中针对艰难梭菌毒素A和毒素B的IgG抗体。
Bioanalysis. 2016 Apr;8(7):611-23. doi: 10.4155/bio-2015-0033. Epub 2016 Mar 11.
8
Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.艰难梭菌疫苗及血清免疫球蛋白G对毒素A的抗体反应。
Infect Immun. 2003 Mar;71(3):1608-10. doi: 10.1128/IAI.71.3.1608-1610.2003.
9
Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.两组分艰难梭菌类毒素疫苗诱导的系统抗体应答可预防仓鼠艰难梭菌相关性疾病。
J Med Microbiol. 2013 Sep;62(Pt 9):1394-1404. doi: 10.1099/jmm.0.056796-0. Epub 2013 Mar 21.
10
Recurrent Clostridioides difficile Infection Is Associated With Impaired T Helper Type 17 Immunity to C difficile Toxin B.复发性艰难梭菌感染与17型辅助性T细胞对艰难梭菌毒素B的免疫功能受损有关。
Gastroenterology. 2021 Mar;160(4):1410-1413.e4. doi: 10.1053/j.gastro.2020.11.043. Epub 2020 Nov 27.
引用本文的文献
1
A Mouse Model of Mild Infection for the Characterization of Natural Immune Responses.用于表征天然免疫反应的轻度感染小鼠模型。
Microorganisms. 2024 Sep 24;12(10):1933. doi: 10.3390/microorganisms12101933.
2
Therapeutics involved in managing initial and recurrent infection: An updated literature review.治疗初发和复发性感染的疗法：文献综述更新
World J Gastrointest Pharmacol Ther. 2024 Sep 5;15(5):95467. doi: 10.4292/wjgpt.v15.i5.95467.
3
Novel Biomarkers, Including PCR Cycle Threshold, for Predicting Recurrent Clostridioides difficile Infection.新型生物标志物，包括 PCR 循环阈值，可预测复发性艰难梭菌感染。
Infect Immun. 2023 Apr 18;91(4):e0009223. doi: 10.1128/iai.00092-23. Epub 2023 Mar 28.
4
infection: traversing host-pathogen interactions in the gut.感染：穿越肠道中的宿主-病原体相互作用。
Microbiology (Reading). 2023 Feb;169(2). doi: 10.1099/mic.0.001306.
5
Host Immune Responses to Surface S-Layer Proteins (SLPs) of .宿主对……表面S层蛋白（SLPs）的免疫反应
Microorganisms. 2023 Feb 2;11(2):380. doi: 10.3390/microorganisms11020380.
6
Antigen-Specific vs. Neutralizing Antibodies Against Conditioned Media of Patients With Infection: A Prospective Exploratory Study.针对感染患者条件培养基的抗原特异性抗体与中和抗体：一项前瞻性探索性研究。
Front Microbiol. 2022 Feb 24;13:859037. doi: 10.3389/fmicb.2022.859037. eCollection 2022.
7
Humoral Immune Response to Toxins A and B in Hospitalized Immunocompromised Patients With Infection.住院免疫功能低下感染患者对毒素A和毒素B的体液免疫反应
Open Forum Infect Dis. 2021 Jun 1;8(7):ofab286. doi: 10.1093/ofid/ofab286. eCollection 2021 Jul.
8
Anti-toxin antibody is not associated with recurrent Clostridium difficile infection.抗毒素抗体与复发性艰难梭菌感染无关。
Anaerobe. 2021 Feb;67:102299. doi: 10.1016/j.anaerobe.2020.102299. Epub 2020 Nov 21.
9
Enhanced Humoral Immune Responses against Toxin A and B of is Associated with a Milder Disease Manifestation.针对[具体病原体]毒素A和B的增强体液免疫反应与较轻的疾病表现相关。 （你提供的原文中“Enhanced Humoral Immune Responses against Toxin A and B of ”这里“of ”后面缺少具体内容，我按常规补充了[具体病原体]，你可根据实际情况修改）
J Clin Med. 2020 Oct 10;9(10):3241. doi: 10.3390/jcm9103241.
10
The Bioinformatic and In Vitro Studies of Clostridioides Difficile Aminopeptidase M24 Revealed the Immunoreactive KKGIK Peptide.艰难梭菌氨肽酶 M24 的生物信息学和体外研究揭示了免疫反应性 KKGIK 肽。
Cells. 2020 May 7;9(5):1146. doi: 10.3390/cells9051146.
本文引用的文献
1
Characterisation and carriage ratio of Clostridium difficile strains isolated from a community-dwelling elderly population in the United Kingdom.从英国社区居住的老年人群体中分离出的艰难梭菌菌株的特征和携带率。
PLoS One. 2011;6(8):e22804. doi: 10.1371/journal.pone.0022804. Epub 2011 Aug 23.
2
The role of toxin A and toxin B in Clostridium difficile infection.艰难梭菌感染中毒素 A 和毒素 B 的作用。
Nature. 2010 Oct 7;467(7316):711-3. doi: 10.1038/nature09397. Epub 2010 Sep 15.
3
Treatment with monoclonal antibodies against Clostridium difficile toxins.针对艰难梭菌毒素的单克隆抗体治疗。
N Engl J Med. 2010 Jan 21;362(3):197-205. doi: 10.1056/NEJMoa0907635.
4
Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).血清抗毒素 B 抗体与预防复发性艰难梭菌感染（CDI）相关。
Vaccine. 2010 Jan 22;28(4):965-9. doi: 10.1016/j.vaccine.2009.10.144. Epub 2009 Nov 24.
5
Toxin B is essential for virulence of Clostridium difficile.毒素B对于艰难梭菌的毒力至关重要。
Nature. 2009 Apr 30;458(7242):1176-9. doi: 10.1038/nature07822. Epub 2009 Mar 1.
6
Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.复发性艰难梭菌感染临床预测规则的前瞻性推导与验证
Gastroenterology. 2009 Apr;136(4):1206-14. doi: 10.1053/j.gastro.2008.12.038. Epub 2008 Dec 13.
7
Increasing seroprevalence of Clostridium difficile in an adult Danish general population.丹麦成年普通人群中艰难梭菌血清阳性率上升。
Epidemiol Infect. 2009 Feb;137(2):278-83. doi: 10.1017/S0950268808000800. Epub 2008 May 27.
8
A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea.一项关于夫西地酸和甲硝唑治疗艰难梭菌相关性腹泻初发 episode 的双盲随机对照试验。
注：这里“episode”结合语境可理解为“发病情况”等类似意思，具体准确含义需结合更多医学背景知识进一步确定。
J Antimicrob Chemother. 2004 Jul;54(1):211-6. doi: 10.1093/jac/dkh278. Epub 2004 May 26.
9
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.针对毒素A的抗体反应与预防艰难梭菌复发性腹泻之间的关联。
Lancet. 2001 Jan 20;357(9251):189-93. doi: 10.1016/S0140-6736(00)03592-3.
10
Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.艰难梭菌无症状携带与抗毒素A的IgG抗体血清水平
N Engl J Med. 2000 Feb 10;342(6):390-7. doi: 10.1056/NEJM200002103420604.
Zotero 插件